746.58

0.10% -0.78

After Hours: 745.79 -0.79 -0.11%

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $746.58, with a volume of 901.79K. It is down -0.10% in the last 24 hours and up +1.87% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$747.36

Open:

$751.48

24h Volume:

901.79K

Relative Volume:

1.28

Market Cap:

$78.93B

Revenue:

$14.34B

Net Income/Loss:

$4.50B

P/E Ratio:

17.96

EPS:

41.5626

Net Cash Flow:

$3.77B

1W Performance:

-0.97%

1M Performance:

+1.87%

6M Performance:

+27.68%

1Y Performance:

+27.51%

1-Day Range:

$740.47

$755.78

1-Week Range:

$734.12

$758.61

52-Week Range:

$476.49

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1109)

Industry

Biotechnology (620)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,410

Twitter

@regeneron

Next Earnings Date

2026-04-29

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	746.58	79.01B	14.34B	4.50B	3.77B	41.56
VRTX Vertex Pharmaceuticals Inc	437.67	111.05B	12.07B	3.95B	3.19B	15.33
ARGX Argen X Se Adr	793.22	50.08B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	310.58	41.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.41	34.67B	5.36B	287.73M	924.18M	2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-26	Resumed	Piper Sandler	Overweight
Mar-06-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-24-25	Initiated	HSBC Securities	Buy
Nov-24-25	Resumed	Truist	Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-14-25	Upgrade	Citigroup	Neutral → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

Apr 22, 2026

FDA approves dupilumab for chronic spontaneous urticaria in children 2 years and older - Contemporary Pediatrics

Apr 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria - The Manila Times

Apr 22, 2026

First biologic for kids as young as 2 wins U.S. approval for chronic hives - Stock Titan

Apr 22, 2026

Raymond James reiterates Outperform on Regeneron stock at $910 target By Investing.com - Investing.com Canada

Apr 22, 2026

Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran - Citeline News & Insights

Apr 22, 2026

Fund Update: 25,606 REGENERON PHARMACEUTICALS (REGN) shares added to WestEnd Advisors, LLC portfolio - Quiver Quantitative

Apr 22, 2026

REGN: Flexible C5 inhibition strategy shows strong efficacy in PNH and gMG, with major catalysts ahead - TradingView

Apr 22, 2026

Regeneron (REGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 22, 2026

TD Waterhouse Canada Inc. Has $5.29 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 22, 2026

REGN: Cemdisiran ± pozelimab shows late-stage efficacy and commercial promise in gMG, PNH, and GA - TradingView

Apr 22, 2026

Regeneron Pharmaceuticals (REGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 22, 2026

Non-Proliferative Diabetic Retinopathy Market to Reach USD - openPR.com

Apr 22, 2026

Apr 21, 2026

Regeneron’s Lunsekimig Data Expand Immunology Story Beyond Dupixent Dependency - simplywall.st

Apr 21, 2026

Regeneron (REGN) Presents NIMBLE Trial Findings for Cemdisiran i - GuruFocus

Apr 21, 2026

Regeneron Pharmaceuticals Announces Positive Phase 3 NIMBLE Trial Results For Cemdisiran In gMG - TradingView

Apr 21, 2026

Regeneron announces publication of Phase 3 NIMBLE trial results - TipRanks

Apr 21, 2026

Regeneron submits U.S. application for gMG treatment cemdisiran By Investing.com - Investing.com Canada

Apr 21, 2026

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial - The Manila Times

Apr 21, 2026

A shot every 12 weeks controlled myasthenia gravis in Phase 3 - Stock Titan

Apr 21, 2026

Zurcher Kantonalbank Zurich Cantonalbank Sells 17,601 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 21, 2026

Private Wealth Partners LLC Purchases Shares of 2,270 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 21, 2026

Graves' Ophthalmopathy Treatment Market to Reach USD 3.01 - openPR.com

Apr 21, 2026